[Cusabio] Your First Choice for CAR-T in Tumor Research: EGFR, CD19, BCMA, CD20, Claudin 18.2, GPC3,
작성자
abbabio
작성일자
2022-05-10
조회수
263
If you are unable to see the message below, click here to view.
Chimeric antigen receptor (CAR) T-cell therapy is a kind of cancer treatment that uses cells from your own immune system. CAR-T is able to sense cells with specific proteins on its surface through its own receptors, lock infected cells and cancer cells in this way, and then kill them. Apparently, CAR-T cell therapy has already exhibited dramatically efficacy in tumors.
CUSABIO has successfully developed over several active proteins, covering the most popular CAR-T cell therapy targets in solid tumors and haematological tumors. All of these proteins with high purity and high binding activity.
1) the favored CAR-T therapy for haematological tumors including CD19, BCMA, CD20, CD22, CD38...
Based on the SEQUEST from database of Mammalian Cell host and target protein, the LC-MS/MS Analysis result of CSB-MP007479HU could indicate that this peptide derived from Mammalian Cell-expressed Recombinant Human EGFR.
Generally speaking, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy. But over the past several years, immunotherapy, one type of therapies enlists and strengthens...
Actually, CAR-T technology has been used for many years, but it has been improved into clinical use in recent years as a new type of cell therapy. It has a remarkable effect on the treatment of acute leukemia and non-Hodgkin's lymphoma...
Albeit CAR-T therapy is faced with the inherent obstacles of solid tumors, a growing number of promising coping strategies have gradually emerged. Many studies have focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment...
